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METHODS: The OPMS-J is 12-month, prospective, observa-
tional study of the health outcomes associated with olanzapine
treatment in Japan. Patient enrollment started before November
2003, and completed by July 2004. A total of 1955 out/in-
patients were enrolled in the OPMS-J, of whom 1849 were
considered as qualiﬁed subjects for the analysis of effectiveness.
Four types of outcomes were measured in the study: social activ-
ity (social activity was assessed using single-item questions that
asked whether the patient was involved in any social interactions
in the previous 4 weeks), EQ-5D, Clinical Global Impression-
Schizophrenia scale (CGI-SCH) and the maintenance rate of
olanzapine. Regarding the maintenance rate of olanzapine, the
OPMS-J was compared with the SOHO study, as an external
control, with typical and atypical antipsychotic medication
including olanzapine. RESULTS: The three outcomes, i.e., social
activity, EQ-5D and the CGI-SCH, all, signiﬁcantly improved
when the scores at the baseline were statistically compared with
those at the endpoint of 12-month follow-up or the end of the
surveillance (p < 0.001). Also, the deterioration rate of patients
status was observed as less than 5% in the group measured with
the CGI-SCH. The maintenance rate of olanzapine in the
OPMS-J was 68.25% (n = 1262) in the 12-month follow-up
duration, which is similar to that of SOHO study reported at the
12-month endpoint, ranging from 79.5% to 51.4%. CONCLU-
SION: The improvement of patient-reported outcomes with
respect to olanzapine was conﬁrmed in the OPMS-J, a post
marketing surveillance in Japan. Also, the maintenance rate of
olanzapine in Japan was similar as that in the European study.
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OBJECTIVES: To compare the efﬁcacy of antipsychotics in the
treatment of negative symptoms of schizophrenia. METHODS:
Studies were identiﬁed by searching for randomized, double-
blind, placebo-controlled trials reporting data on efﬁcacy of
antipsychotics on negative symptoms in schizophrenia. A struc-
tured literature review was conducted in the following databases:
Pubmed, The Cochrane Central Register of Controlled Trials
(CENTRAL), Proquest Health and Medical Complete, Science
Citation Index Expanded, and Current Contents Connect. The
outcome measure was the mean change in negative symptoms
score from baseline to end-point on the PANSS-N, SANS, and
BPRS retardation factor (BPRS-R) scales. As we obtained data
from different assessment instruments to be combined, we chose
a standardized statistic—Cohen’s d—which is a type of standard-
ized mean difference. The Der-Simonian and Laird random
effects model was used to synthesize data. All calculations were
made using STATA 8.2, with 95% conﬁdence intervals and sig-
niﬁcance level of 0.05. RESULTS: A total of 46 homogeneous
trials (Q = 45.18, df = 50, p = 0.667, I2 = 0%) were included;
4 with amisulpride, 3 with ziprasidone, 9 with olanzapine, 8
with risperidone, 11 with quetiapine, 8 with haloperidol, 2 with
zotepine, and 1 with chlorpromazine. Ranked effect sizes
(Cohen’s d) favoring active treatment against placebo were for
amisulpride; 0.52 (p < 0.001), ziprasidone; 0.50 (p < 0.001),
olanzapine; 0.43 (p < 0.001), risperidone; 0.40 (p < 0.001), que-
tiapine; 0.36 (p < 0.001), haloperidol; 0.34 (p < 0.001), zotepine;
0.31 (p = 0.11), and chlorpromazine; 0.12 (p = 0.532). CON-
CLUSION: The efﬁcacy of antipsychotics on negative symptoms
seems to be drug-dependent. Amisulpride and ziprasidone
showed better overall effects than the other antipsychotics.
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OBJECTIVES: To review systematically the comparative efﬁcacy
of second-generation antidepressants for the treatment of acute
phase major depressive disorder (MDD) in adults. METHODS:
To identify relevant articles we searched MEDLINE®, Embase,
The Cochrane Library, and the International Pharmaceutical
Abstracts from 1980 to 2006 (February). We included double-
blinded, randomized controlled trials (RCTs) of good or fair
internal validity. If data were sufﬁcient, we conducted relative
beneﬁt and effect size meta-analyses to assess the comparative
efﬁcacy of two drugs. If not enough data were available for
meta-analyses, we conducted adjusted indirect comparisons
based on placebo controlled RCTs. For adjusted indirect com-
parisons we employed meta-regression and network meta-
analysis as statistical methods. RESULTS: Overall we included
108 studies. Data was sufﬁcient to conduct meta-analyses on four
comparisons. For the other 62 possible comparisons we con-
ducted adjusted indirect comparisons. Outcomes of interest were
relative beneﬁt (RB) of response. We found statistically signiﬁ-
cant differences in response rates favoring escitalopram over
citalopram (RB: 1.19; 95% CI, 1.08–1.30), sertraline over ﬂu-
oxetine (RB: 1.11; 95% CI, 1.01–1.25), and venlafaxine over
ﬂuoxetine (RB: 1.12; 95% CI, 1.00–1.25). However, these dif-
ferences are modest and likely not clinically signiﬁcant. Adjusted
indirect comparisons did not indicate differences in efﬁcacy
among second-generation antidepressants. In other ﬁndings, mir-
tazapine had a faster onset of action, bupropion led to improved
sexual functioning, and nefazodone and trazodone to improved
sleep quality than comparator drugs. No differences in effective-
ness, adherence, or efﬁcacy in subgroups could be detected.
CONCLUSION: Our ﬁndings indicate that the current evidence
does not warrant the choice of one second-generation antidepres-
sant over another based on differences in efﬁcacy and effective-
ness. However, other differences with respect to onset of action
and some aspects of quality of life may be relevant for the choice
of a medication.
PMH6
ATTAINING REMISSION OF DEPRESSIVE SYMPTOMS INTHE
PIVOTAL RANDOMISED CLINICALTRIALS OF DULOXETINE
IN MAJOR DEPRESSION.WHICH ARETHE MOST
EFFICACIOUS DOSES?
Ballesteros J, Callado LF, Gutierrez M
University of the Basque Country, UPV-EHU, Leioa,Vizcaya, Spain
OBJECTIVES: To analyse and compare the remission rates
reported for various doses of duloxetine (DXT) in the pivotal
RCTs conducted in major depression (MD). METHODS:
Number of remitters (intention-to-treat approach) and number
of patients randomised to the different treatment arms were
obtained from the Lilly webpage (www.lillytrials.com/results/
by_product/results_cymbalta.html). Data from 6 RCTs including
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